Candel Therapeutics, Inc. (CADL) Stock Price & Analysis

Candel Therapeutics, Inc. (CADL) closed at USD 8.67 on Wednesday, October 28, 2026, up 5.09% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 8.25; the Oct 28, 2026 session ranged USD 8.13–8.69 on volume of 663,002 shares. Market capitalization is $663.42M, with a 52-week range of USD 4.35–14 (NGM). Source: Nexqual, retrieved October 29, 2026 at 09:22 UTC.

Also available as compact Markdown for AI agents: nexqual.com/CADL.md

Key facts (CADL)

• Insider open-market sales, last ~7 months: 4 Form 4 filings, $3.6M; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 2.00 on a 1–5 scale) (10 analysts), mean target USD 22.11 (range 15–29).
• Total return with dividends: 1Y +57.9% vs S&P 500 +13.6%; 5Y -22.8% vs S&P 500 +79.8%.
• Next earnings: 2026-11-12, EPS estimate USD -0.31, revenue estimate $0K.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CADL)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (CADL)

P/B 5.3x · FCF yield -8.64% · Earnings yield -13.34%

Insider sales (SEC Form 4, open-market, last ~7 months) (CADL)

4 of 4 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (CADL)

Consensus Buy (mean 2.00 on a 1–5 scale), 10 analysts; mean target USD 22.11 (low 15, high 29).

Rating changes, last 120 days:

Total return (dividends reinvested) (CADL)

CADL earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

CADL recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

CADL suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 12, 2026.

CADL company outlook (results filed Aug 13, 2026)

• “Based on current operating plans, the Company expects that its existing cash and cash equivalents, as of June 30, 2026, will be sufficient to fund operations into Q1 2028.”

Quoted word-for-word from the SEC 8-K results press release.

CADL analyst estimates and revisions

CADL options: expected move

Options price a move of about ±36.5% (±$3.10) by Nov 20, 2026, which includes earnings on Nov 12, 2026. Over the last 8 reports the stock moved ±7.2% on average.

30-day implied volatility 103.2% vs 58.3% realized over the last 30 trading days. Put/call ratio (volume) 9.28. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 09:22 UTC)

Technical Analysis (CADL)

Nexqual's technical model rates CADL "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 29, 2026 at 09:22 UTC.

Analyst Ratings (CADL)

Wall Street analysts rate CADL "Buy" based on 10 analysts, with a mean price target of USD 22.11 (range USD 15–29), per Nexqual as of October 29, 2026 at 09:22 UTC.

Earnings (CADL)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 09:22 UTC.

Financials & Fundamentals (CADL)

Source: Nexqual, October 29, 2026 at 09:22 UTC.

Financial Health Score (CADL)

Nexqual rates Candel Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 09:22 UTC.

Ownership (CADL)

Source: Nexqual, October 29, 2026 at 09:22 UTC.

Leadership (CADL)

Candel Therapeutics, Inc. is led by Paul-Peter Tak FOCIS, President, CEO & Director, per Nexqual as of October 29, 2026 at 09:22 UTC.

Major Backers & Investors (CADL)

Notable institutional backers of Candel Therapeutics, Inc. include Fidelity, FMR, LLC, RTW Investments LP, according to Nexqual as of October 29, 2026 at 09:22 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 09:22 UTC.

From Candel Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)

Key Strengths & Strategy (as disclosed to the SEC)

• We have also designed additional novel viral immunotherapy candidates using our proprietary enLIGHTEN™ Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors.
• Therefore, this study aimed to assess whether adding aglatimagene plus valacyclovir to standard of care (SoC) radiotherapy could improve disease-free survival (DFS) in patients pursuing curative treatment, a primary endpoint established in the SPA with the FDA.
• We are in ongoing dialogue with the FDA in preparation for the Company's anticipated submission of a Biologics License Application (BLA) for aglatimagene in prostate cancer in the fourth quarter of 2026.
• Key attributes of the enLIGHTEN™ Discovery Platform include: Strong focus on human biology, including deep phenotyping of human tumors, to increase probability of success Data driven selection of the payload.

Legal & Regulatory Risks (Item 1A, quoted)

• The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. If we are not able to obtain, or experience delays in obtaining, required regulatory approvals, we will not be able to commercialize aglatimagene, linoserpaturev and future product candidates as expected, and our ability to generate revenue may be materially impaired.
• Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies.
• The FDA's agreement to a Special Protocol Assessment with respect to the study design of our pivotal phase 3 clinical trial of aglatimagene in newly diagnosed localized prostate cancer in intermediate and high-risk patients does not guarantee any particular outcome from regulatory review, including ultimate approval, and may not lead to a successful review or approval process.
• We may seek approval of certain of our current or future product candidates using the FDA's accelerated approval pathway.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 09:22 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt